Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond-Reference-Cited by-同舟云学术

Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond

Published:2024-01 Issue:1 Volume:23 Page:
ISSN:2046-2484
Container-title:Clinical Liver Disease
language:en
Short-container-title:

Author:

Björnsson Helgi K.¹^ORCID,Björnsson Einar S.²³^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Landspitali—The National University Hospital of Iceland, Reykjavik, Iceland

3. Faculty of Medicine, University of Iceland, Reykjavik, Iceland

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference48 articles.

1. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study;Reuben;Ann Intern Med,2016

2. Drug-induced liver injury—Types and phenotypes;Hoofnagle;N Engl J Med,2019

3. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports;Björnsson;Hepatology,2016

4. Case definition and phenotype standardization in drug-induced liver injury;Aithal;Clin Pharmacol Ther,2011

5. Sulphasalazine and mesalazine: Serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines (multiple letters);Logan;Gut,2003

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A state-of-the-art update on hepatotoxicity: Introduction to the special series on drug-induced liver injury;Clinical Liver Disease;2024-01